Heart with interwoven vessels, symbolizing systemic right ventricle, enveloped in protective light.

Systemic Right Ventricle: Can Valsartan Make a Difference?

Jordan Keane monogram
Jordan Keane in Health & Wellness October 2026 • 4 min read.

"Exploring the impact of valsartan on heart health for patients with systemic right ventricles."


For individuals who have undergone an atrial switch procedure for complete transposition of the great arteries (TGA) or those with congenitally corrected transposition of the great arteries (ccTGA), the gradual decline of the systemic right ventricle (RV) poses a significant and unavoidable challenge. This decline is a primary contributor to both morbidity and mortality, underscoring the critical need for effective interventions.

Currently, the data available regarding the use of renin-angiotensin-aldosterone system (RAAS) inhibitors in this specific patient population is limited. The conclusions drawn from existing studies are often inconsistent, primarily due to the small number of patients involved. This scarcity of robust data highlights the necessity for further research to determine the true potential of these treatments.

The Valsartan in the Systemic Right Ventricle (VAL-SERVE) trial, we aimed to build on previous findings to investigate the long-term effects of valsartan on clinical outcomes in patients with systemic right ventricles. Our goal was to provide more definitive insights into how this medication can impact this vulnerable population, and to assess the longer-term effects of valsartan on clinical outcomes in patients enrolled in the VAL-SERVE trial

AI Search Multiple angles on this topic

Heart Failure Burden and Treatment Gaps

HF Stats 2025 reports that approximately 6.7 million Americans older than 20 have heart failure, with prevalence projected to rise to 8.7 million by 2030. Heart failure contributed to 425,147 deaths in the United States in 2022, representing 45% of cardiovascular deaths. Although use of sacubitril/valsartan has increased greatly in the United States, a substantial proportion of eligible patients with heart failure with reduced ejection fraction did not receive it, and only one in five dispensed prescriptions used the target strength.

Guideline-Based Therapy and Dose Uncertainty

The 2022 AHA/ACC/HFSA guideline presents an evidence-based approach to heart-failure treatment intended to improve quality of care and align management with patients’ interests. Sacubitril/valsartan reduces mortality compared with enalapril in patients with heart failure with reduced ejection fraction, but its effects on functional capacity remain uncertain. Although guidelines emphasize uptitration to trial-validated target doses, emerging evidence suggests that submaximal doses may offer comparable clinical benefit across diverse patients, leaving optimal real-world dosing uncertain.

From Valsartan to ARNI Therapy

Valsartan is described as a potent, orally active, selective angiotensin II receptor blocker used in hypertension, heart failure, and after myocardial infarction. It was developed as an alternative to angiotensin-converting enzyme inhibitors and provides direct blockade of the renin-angiotensin-aldosterone system. Later, the PARADIGM-HF trial showed that combining valsartan with sacubitril improved heart-failure prognosis more effectively than previous therapy in patients with reduced ejection fractions.

Valsartan and Systemic RV: What the Study Revealed

Heart with interwoven vessels, symbolizing systemic right ventricle, enveloped in protective light.

Between 2006 and 2009, a group of 88 adults was selected and divided randomly into two groups. One group received valsartan, and the other received a placebo. This treatment was administered consistently for three years. The researchers defined specific endpoints to measure the effectiveness of the treatments. These included overall survival and the absence of clinical events such as arrhythmia, heart failure, the necessity for tricuspid valve surgery, and death. These measures helped provide a clear picture of the treatment's impact on patient health.

Following the initial trial period, the use of cardiac medications and the duration of follow-up were similar across both groups, with an average of 8.3 years. During this extended observation, six patients died—three from the valsartan group and three from the placebo group. This indicated no significant difference in survival between the two treatments (P=0.999).

  • No significant differences were observed in either the combined or individual clinical endpoints between the groups. The long-term survival rates free from events were approximately 50% in the valsartan group and 34% in the placebo group.
  • However, in patients who were symptomatic, valsartan significantly decreased the risk of events compared to the placebo.
  • The benefits were noted only in symptomatic patients, suggesting that valsartan’s protective effects are more pronounced in those already experiencing symptoms.
AI Search Multiple angles on this topic

A Broader Evidence Base for Sacubitril/Valsartan

A 2025 review describes heart failure as a global health challenge associated with high morbidity and mortality, reduced quality of life, and substantial economic burden. It highlights the PARAMOUNT trial as the first randomized, double-blind trial assessing the safety and efficacy of an angiotensin receptor-neprilysin inhibitor in heart failure with preserved ejection fraction. Sacubitril/valsartan is also recommended by the 2022 American Heart Association, American College of Cardiology, and Heart Failure Society of America guideline for patients with reduced ejection fraction and New York Heart Association class II–III heart failure.

The Systemic Right-Ventricle Evidence Gap

The cited valsartan study found no significant effect after three years of treatment on systemic right-ventricular ejection fraction. The reported treatment effect was 1.3%, with a 95% confidence interval from −1.3% to 3.9% and P=0.34. The study also found no significant improvement in maximum exercise capacity or quality of life, limiting the case for valsartan as a proven therapy for systemic right-ventricular dysfunction.

Sacubitril/Valsartan Versus Established Options

In sacubitril/valsartan, the 103 mg valsartan component is equivalent to 160 mg of standard valsartan. Comparative research commonly evaluates outcomes such as first and recurrent heart-failure hospitalizations and cardiovascular death. Evidence comparing sacubitril/valsartan with enalapril has not been uniform: randomized trials show superiority for reducing N-terminal pro-B-type natriuretic peptide levels, while findings for cardiovascular mortality, heart-failure rehospitalization, and all-cause mortality have been mixed.

Interestingly, further analysis, including assessments of repeated events and on-treatment usage of renin-angiotensin-aldosterone system (RAAS) inhibitors, did not alter the primary results. This consistency reinforces the conclusion that while valsartan may not improve overall survival in all systemic RV patients, it does offer a protective effect against clinical events for those who are symptomatic.

The Takeaway: Valsartan's Targeted Benefits

In summary, while valsartan treatment does not lead to improved survival rates in all patients with systemic right ventricle, it is associated with a decreased risk of clinical events in symptomatic patients. These findings suggest a targeted benefit, emphasizing the importance of identifying and treating symptomatic individuals to improve their long-term outcomes. Further research and prospective studies are essential to fully understand the role of valsartan and similar therapies in this specific population.

AI Search Multiple angles on this topic

Evidence Across Heart-Failure Phenotypes

An updated meta-analysis comparing sacubitril-valsartan with standard treatment included nine randomized controlled trials and 15,939 patients. A separate systematic review examined its effects in patients with mid-range ejection fractions. Another meta-analysis evaluated quality of life in chronic heart failure compared with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, reflecting the broader effort to assess benefits beyond mortality and hospitalization.

Expansion of Valsartan-Based Care

The global valsartan market is described as a critical segment of cardiovascular therapeutics, driven by use of valsartan as an angiotensin II receptor blocker for hypertension and heart failure. One market forecast values the global sacubitril valsartan sodium market at approximately $4.2 billion in 2024 and projects it to reach around $7.5 billion by 2034. Reported growth drivers include expanding clinical use in chronic heart failure, broader hospital and ambulatory care pathways, increasing cardiovascular disease and hypertension, and development of generic formulations.

Treatment in Older Adults

The PARACHUTER registry was a multicenter prospective registry evaluating real-world angiotensin receptor-neprilysin inhibitor use among Japanese patients with heart failure. Its analysis compared biomarker response and tolerability between patients aged 80 years or older and those younger than 80. This design focuses on how sacubitril/valsartan performs in routine care for older adults, rather than only in selected clinical-trial populations.

Valsartan and placebo showed different changes in right-ventricle size

  • 15 mLRight ventricular end-diastolic volume increased more with placebo than with valsartan: the between-group difference in increase was 15 mL.[1]

How the valsartan findings fit the wider right-heart evidence

The broader discussion of RAAS inhibition in congenital heart disease cautions that trial limitations may help explain the lack of demonstrated effects, while also pointing to possible intrinsic reasons. The results therefore sit within an unsettled question, rather than proving that the treatment pathway cannot work.[2]

Context from patients with congenital heart disease indicates that RAAS activation was observed in symptomatic patients, unlike other neurohormones, which were increased in both symptomatic and asymptomatic patients. This offers a possible biological context for why symptom status may matter, but does not establish the mechanism behind the valsartan result.[2] [3]

Most studies discussed in the broader review found no benefit of RAAS inhibition for systemic right-ventricle function or exercise capacity, although a very small losartan crossover study reported improvement in both. This mixed background makes the valsartan findings on size and symptom-specific events relevant, but not conclusive evidence of a general effect.[1] [2] [3]

What remains unresolved about valsartan in a systemic right ventricle

  • Why was the lower event risk reported for symptomatic patients, and how much does RAAS activation explain that pattern? The available context links activation with symptoms but does not establish a causal explanation for the treatment result.[2] [3]

Terms used in the evidence

RAAS inhibition
Treatment that inhibits the renin–angiotensin–aldosterone system.[2]

Sources

  1. Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. (pubmed.ncbi.nlm.nih.gov)
  2. The renin–angiotensin–aldosterone-system and right heart failure in congenital heart disease (pmc.ncbi.nlm.nih.gov)
  3. Long-term clinical outcomes of valsartan in patients with a systemic right ventricle: Follow-up of a multicenter randomized controlled trial. (pubmed.ncbi.nlm.nih.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What exactly is a systemic right ventricle and why is it a concern?

A systemic right ventricle refers to the right ventricle taking on the role of the main pumping chamber of the heart, typically the left ventricle. This occurs in conditions like complete transposition of the great arteries (TGA) after an atrial switch procedure, or congenitally corrected transposition of the great arteries (ccTGA). The systemic right ventricle is significant because it is not designed for this high-pressure role, leading to a gradual decline in function and increased risk of heart failure, arrhythmia, and other adverse events. Therefore, finding ways to support and protect the systemic right ventricle is crucial for improving long-term outcomes for affected individuals.

2

What is valsartan, and how might it help with heart conditions?

Valsartan is a medication that belongs to a class of drugs known as angiotensin II receptor blockers (ARBs). It works by blocking the effects of angiotensin II, a hormone that can cause blood vessels to constrict. By blocking angiotensin II, valsartan helps to relax blood vessels, lower blood pressure, and reduce the workload on the heart. Valsartan is significant because it is one of the renin-angiotensin-aldosterone system (RAAS) inhibitors being explored for its potential to protect the systemic right ventricle in patients with conditions like TGA or ccTGA. However, the effectiveness of valsartan in this specific population has been uncertain, prompting studies like the VAL-SERVE trial to investigate its impact on clinical outcomes.

3

What was the purpose of the VAL-SERVE trial?

The VAL-SERVE trial was a multicenter randomized controlled trial designed to evaluate the long-term effects of valsartan on clinical outcomes in patients with a systemic right ventricle. In this study, participants were randomly assigned to receive either valsartan or a placebo over a period of three years. The trial aimed to determine whether valsartan could improve overall survival and reduce the occurrence of clinical events such as arrhythmia, heart failure, the need for tricuspid valve surgery, or death. The VAL-SERVE trial is significant because it sought to provide more definitive insights into the potential benefits of valsartan in this vulnerable patient population, addressing the limitations of previous studies with small sample sizes and inconsistent results.

4

What were the main findings of the VAL-SERVE trial regarding valsartan's impact?

The VAL-SERVE trial revealed that valsartan treatment did not lead to improved overall survival rates in all patients with a systemic right ventricle. However, it was associated with a decreased risk of clinical events in patients who were symptomatic. This suggests that valsartan may offer a protective effect against complications like heart failure or arrhythmia specifically for those individuals already experiencing symptoms related to their systemic right ventricle dysfunction. This finding is important because it highlights the potential for targeted treatment with valsartan in symptomatic patients to improve their long-term outcomes, even if it does not impact survival for all patients with a systemic right ventricle.

5

What are RAAS inhibitors, and why are they relevant in the context of a systemic right ventricle?

RAAS inhibitors are a class of medications that includes angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), and aldosterone antagonists. These drugs work by interfering with the renin-angiotensin-aldosterone system (RAAS), a hormonal system that regulates blood pressure and fluid balance in the body. RAAS inhibitors are significant because they have been shown to have protective effects on the heart and blood vessels in various cardiovascular conditions. In the context of a systemic right ventricle, RAAS inhibitors like valsartan are being investigated for their potential to reduce the workload on the right ventricle, prevent remodeling, and improve clinical outcomes. The inconsistent results from studies on RAAS inhibitors in this population highlight the need for further research to determine the optimal use of these medications.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.